[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation]

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):162-4. doi: 10.3760/cma.j.issn.0253-2727.2014.02.022.

[Article in Chinese]

Authors

Min Zhou¹, Xinshan Sha¹, Huiying Qiu¹, Jiannong Cen¹, Hongjie Shen¹, Aining Sun¹, Depei Wu¹

Affiliation

¹ Key Laboratory of Thrombosis and Haemostasis,Ministry of Health, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

PMID: 24606661
DOI: 10.3760/cma.j.issn.0253-2727.2014.02.022

No abstract available

MeSH terms

Adolescent
Adult
Aged
Female
Fusion Proteins, bcr-abl / genetics*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Male
Middle Aged
Mutation
Pilot Projects
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Retrospective Studies

Substances

Fusion Proteins, bcr-abl